Sickle Cell Disease

nRBC is being developed for conjunctive use with the current treatments of RBC transfusion and hydroxyurea therapy to the further reduce stroke, acute chest syndrome and painful vaso-occlusive crisis due to chronic hemolysis in sickle cell patients.


FDA has concurred that nRBC may be developed as a therapeutic for sickle cell disease (SCD) based on its documented efficacy in transgenic SCD mice.   nRBC is a carrier of both a releasable anti-inflammatory carbon monoxide and is a persistent carrier of superoxide dismutase (SOD) activity which provides lasting enhancement of blood flow through the restoration of nitric oxide homeostasis.  Its anti-oxidative stress activities also prevent ischemia, reperfusion and inflammation injuries from vaso-occulsion in the brain (stroke), pulmonary vessels (acute chest syndrome) and elsewhere (painful vaso-occlusive crisis) in SCD patients.